The combination therapies of imatinib and Hsp90 inhibitors slow the inflammation-promoted progression of BCR-ABL1⁺ B-ALL. (A) Diagram of the treatment schedule in BCR-ABL1⁺ B-ALL mouse model. (B) Kaplan-Meier survival curves for the indicated mice with different treatments (n = 8 per group). (C) Monitoring the peripheral blood percentage of GFP⁺ cells in the indicated recipient mice on days 7 and 14 after transplantation. (D) Leukemia burden was determined by measuring the percentages of GFP⁺ cells from the BM, SP, LN, liver, lung, and brain in the indicated recipient mice at day 17 after transplantation. (E) Hematoxylin and eosin staining was performed to examine infiltration of the leukemic cell on spleen paraffin sections. Scale bar represents 20 µm. The data are representative of at least 3 independent experiments. Error bars represent the mean ± standard error of the mean. *P < .05, ** P< .01, ***P < .001. ns indicates no significant differences.